Ikarian Capital’s Merck MRK Stock Holding History

Ikarian Capital’s Portfolio MRK Stock Details MRK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-150,000	Closed	-$11.3M	–	221
2021 Q3	$11.3M	Buy	+150,000	New	+$11.4M	0.79%	33

Other funds holding MRK

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Ikarian Capital's MRK Position: Q3 2023 in Review

Ikarian Capital sold out of Merck (MRK) in Q3 2023, closing a stake of 100,000 shares — an estimated $11.5M sold.

Ikarian Capital first reported a position in MRK in Q1 2023 and held it in 2 quarters. The position peaked at $11.5M in Q2 2023. 3,213 funds tracked by Wall St. Rank hold MRK as of Q3 2023.

Ikarian Capital reported no remaining Merck position as of Q3 2023 after selling out during the quarter.
Ikarian Capital sold 100,000 Merck shares in Q3 2023, an estimated $11.5M.
Ikarian Capital first reported a position in Merck in Q1 2023 and held it in 2 quarters.
Ikarian Capital's Merck position peaked at $11.5M in Q2 2023.
3,213 funds tracked by Wall St. Rank held Merck as of Q3 2023.

Based on Ikarian Capital's 13F filing for Q3 2023, filed 14 Nov 2023.